Drugs / QLF32004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05108779 | Nov 2021 → Dec 2024 | — | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLF32004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05108779 ↗ |